Manipulating human dendritic cell phenotype and function with targeted porous silicon nanoparticles

作者：Stead Sebastian O; McInnes Steven J P; Kireta Svjetlana; Rose Peter D; Jesudason Shilpanjali; Rojas C****es Darling; Warther David; Cunin Frederique; Durand Jean Olivier; Drogemuller Christopher J; Carroll Robert P; Coates P Toby; Voelcker Nicolas H

来源：Biomaterials, 2018, 155: 92-102.

DOI：10.1016/j.biomaterials.2017.11.017

• Dendritic cells
• Immunomodulation
• Nanomedicine
• Nanoparticles
• Porous silicon
• Rapamycin
• Targeting

Dendritic cells (DC) are the most potent antigen-presenting cells and are fundamental for the establishment of transplant tolerance. The Dendritic Cell-Specific Intracellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN; CD209) receptor provides a target for dendritic cell therapy. Biodegradable and high-surface area porous silicon (pSi) nanoparticles displaying anti-DC-SIGN antibodies and loaded with the immunosuppressant rapamycin (Sirolimus) serve as a fit-for-purpose platform to target and modify DC. Here, we describe the fabrication of rapamycin-loaded DC-SIGN displaying pSi nanoparticles, the uptake efficiency into DC and the extent of nanoparticle-induced modulation of phenotype and function. DC-SIGN antibody displaying pSi nanoparticles favourably targeted and were phagocytosed by monocyte-derived and myeloid DC in whole human blood in a time- and dose-dependent manner. DC preconditioning with rapamycin-loaded nanoparticles, resulted in a maturation resistant phenotype and significantly suppressed allogeneic T-cell proliferation.

• 出版日期2018-2